X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (59) 59
oncology (38) 38
aged (29) 29
male (29) 29
female (27) 27
middle aged (27) 27
human necessities (25) 25
hygiene (25) 25
medical or veterinary science (25) 25
preparations for medical, dental, or toilet purposes (25) 25
index medicus (24) 24
adult (20) 20
fluorouracil (19) 19
investigating or analysing materials by determining theirchemical or physical properties (19) 19
measuring (19) 19
physics (19) 19
testing (19) 19
antineoplastic combined chemotherapy protocols - therapeutic use (17) 17
chemotherapy (17) 17
fluorouracil - administration & dosage (17) 17
specific therapeutic activity of chemical compounds ormedicinal preparations (17) 17
cancer (15) 15
biochemistry (14) 14
5-fluorouracil (13) 13
beer (13) 13
chemistry (13) 13
compositions or test papers therefor (13) 13
condition-responsive control in microbiological orenzymological processes (13) 13
enzymology (13) 13
leucovorin - administration & dosage (13) 13
measuring or testing processes involving enzymes, nucleicacids or microorganisms (13) 13
metallurgy (13) 13
microbiology (13) 13
mutation or genetic engineering (13) 13
processes of preparing such compositions (13) 13
spirits (13) 13
vinegar (13) 13
wine (13) 13
colorectal neoplasms - drug therapy (12) 12
treatment outcome (12) 12
life sciences (11) 11
toxicity (11) 11
antineoplastic combined chemotherapy protocols - adverse effects (10) 10
colorectal cancer (10) 10
colorectal neoplasms - pathology (10) 10
pharmacology & pharmacy (10) 10
camptothecin - analogs & derivatives (9) 9
fluorouracil - adverse effects (9) 9
neoplasms - drug therapy (9) 9
research (9) 9
advanced colorectal-cancer (8) 8
aged, 80 and over (8) 8
antineoplastic agents - adverse effects (8) 8
fluoropyrimidines (8) 8
leucovorin (8) 8
trial (8) 8
[ sdv.can ] life sciences [q-bio]/cancer (7) 7
cancer research (7) 7
carcinoma (7) 7
drug administration schedule (7) 7
fluorouracil - pharmacokinetics (7) 7
fluorouracil - therapeutic use (7) 7
metastatic colorectal-cancer (7) 7
time factors (7) 7
1st-line treatment (6) 6
adenocarcinoma - drug therapy (6) 6
antimetabolites, antineoplastic - administration & dosage (6) 6
antimetabolites, antineoplastic - pharmacokinetics (6) 6
antineoplastic agents - pharmacokinetics (6) 6
antineoplastic combined chemotherapy protocols - administration & dosage (6) 6
cell line, tumor (6) 6
dihydropyrimidine dehydrogenase-activity (6) 6
hematology (6) 6
medicine & public health (6) 6
organoplatinum compounds - adverse effects (6) 6
pharmacokinetics (6) 6
phase-ii (6) 6
adenocarcinoma - pathology (5) 5
biochemistry & molecular biology (5) 5
camptothecin - administration & dosage (5) 5
cetuximab (5) 5
colorectal neoplasms - metabolism (5) 5
disease-free survival (5) 5
drug resistance (5) 5
genetic aspects (5) 5
identification (5) 5
infusions, intravenous (5) 5
mononuclear-cells (5) 5
neoplasm metastasis (5) 5
oxaliplatin (5) 5
panitumumab (5) 5
plasma (5) 5
prospective studies (5) 5
[sdv.can]life sciences [q-bio]/cancer (4) 4
animals (4) 4
antineoplastic agents - administration & dosage (4) 4
antineoplastic agents - pharmacology (4) 4
antineoplastic combined chemotherapy protocols - pharmacokinetics (4) 4
c-myc (4) 4
care and treatment (4) 4
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Clinical Oncology, ISSN 0732-183X, 05/2008, Volume 26, Issue 13, pp. 2099 - 2105
Journal Article
Journal Article
BMC cancer, ISSN 1471-2407, 2012, Volume 12, Issue 1, pp. 438 - 438
Background: Integument-related toxicities are common during epidermal growth factor receptor (EGFR)-targeted therapy. Panitumumab is a fully human monoclonal... 
IRINOTECAN FOLFIRI | MANAGEMENT | EFFICACY | Panitumumab | Colorectal cancer | Tolerability | FLUOROURACIL | TUMORS | CHEMOTHERAPY | Quality of life | TRIAL | EGFR INHIBITORS | CETUXIMAB | ONCOLOGY | KRAS | Leucovorin - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Follow-Up Studies | Skin Diseases - genetics | Colorectal Neoplasms - genetics | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Skin Diseases - pathology | Young Adult | Fluorouracil - administration & dosage | Leucovorin - adverse effects | Fluorouracil - adverse effects | Colorectal Neoplasms - drug therapy | Aged, 80 and over | Adult | Camptothecin - administration & dosage | Female | Skin - pathology | Camptothecin - analogs & derivatives | Camptothecin - adverse effects | Skin Diseases - chemically induced | Mutation - drug effects | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Quality of Life | Aged | Colorectal Neoplasms - pathology | Genes, ras | Skin - drug effects | Usage | Patient outcomes | Analysis | Dosage and administration | Research | Drug therapy | Antimitotic agents | Cancer patients | Care and treatment | Chemotherapy | Epidermal growth factor | Monoclonal antibodies | Skin | Metastasis | Antineoplastic agents | Patient compliance | Cancer | Biotechnology industry
Journal Article
Journal Article
Journal Article
Journal of Cancer Research and Clinical Oncology, ISSN 0171-5216, 1/2012, Volume 138, Issue 1, pp. 65 - 72
Panitumumab monotherapy is approved for KRAS wild-type (WT) metastatic colorectal cancer (mCRC) progressing after standard chemotherapy. This study evaluated... 
Fully human monoclonal antibody | Chemotherapy | Medicine & Public Health | Hematology | Panitumumab | Cancer Research | Internal Medicine | Oncology | Metastatic colorectal cancer | LEUCOVORIN | INITIAL TREATMENT | OXALIPLATIN | FLUOROURACIL | FOLFIRI | PHASE-III TRIAL | GROWTH-FACTOR RECEPTOR | CETUXIMAB | ONCOLOGY | IRINOTECAN | KRAS | Camptothecin - adverse effects | Leucovorin - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Colorectal Neoplasms - genetics | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Disease-Free Survival | Fluorouracil - administration & dosage | Leucovorin - adverse effects | Fluorouracil - adverse effects | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Colorectal Neoplasms - drug therapy | Camptothecin - administration & dosage | Female | Aged | Genes, ras | Camptothecin - analogs & derivatives | Complications and side effects | Cancer patients | Care and treatment | Oncology, Experimental | Colorectal cancer | Monoclonal antibodies | Leucovorin | Metastasis | Research | Fluorouracil | Cancer | Index Medicus | Clinical Medicine | Medical and Health Sciences | Medicin och hälsovetenskap | Metastatic colorectal | cancer | Klinisk medicin | Cancer and Oncology | Cancer och onkologi
Journal Article
SEMINARS IN ONCOLOGY, ISSN 0093-7754, 10/2002, Volume 29, Issue 5, pp. 21 - 33
Neurotoxicity is the most frequent dose-limiting toxicity of oxaliplatin. Acute neurotoxicity is characterized by the rapid onset of cold-induced distal... 
ORMAPLATIN TETRAPLATIN | NEUROPATHIC PAIN | NERVOUS-SYSTEM | ONCOLOGY | ROOT GANGLION NEURONS | COLORECTAL-CANCER | GATED SODIUM-CHANNELS | OVARIAN-CANCER | ION-CHANNEL MUTATIONS | PHASE-I | SENSORY NEURONS
Journal Article
Investigational New Drugs, ISSN 0167-6997, 12/2018, Volume 36, Issue 6, pp. 1060 - 1071
Background Aurora kinase overexpression or amplifications are associated with high proliferation, poor prognosis, and therapeutic resistance in human tumors.... 
Medicine & Public Health | AMG 900 | pan-Aurora kinase inhibitor | Oncology | Aurora kinase | Pharmacology/Toxicology | Antimitotic | PROGNOSIS | OVARIAN-CANCER | CELL-LINES | ONCOLOGY | DANUSERTIB | PROSTATE-CANCER | CLINICAL-TRIALS | PHARMACOLOGY & PHARMACY | CARCINOMA | PROGRESSION | METASTATIC BREAST | Phthalazines - pharmacokinetics | Humans | Middle Aged | Aurora Kinases - antagonists & inhibitors | Male | Protein Kinase Inhibitors - adverse effects | Dose-Response Relationship, Drug | Biomarkers, Tumor - metabolism | Adult | Female | Protein Kinase Inhibitors - pharmacokinetics | Aurora Kinases - metabolism | Phthalazines - administration & dosage | Administration, Oral | Treatment Outcome | Neoplasms - drug therapy | Protein Kinase Inhibitors - administration & dosage | Maximum Tolerated Dose | Phthalazines - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Progression-Free Survival | Aged | Neoplasm Staging | Neoplasms - pathology | Phthalazines - adverse effects | Cohort Studies | Genetic aspects | Research | Drug therapy | Tumors | Ovarian carcinoma | Toxicity | p53 Protein | Prophylaxis | Taxane | Ovarian cancer | Castration | Granulocyte colony-stimulating factor | Platinum | Colony-stimulating factor | Expansion | Neutropenia | Thrombocytopenia | Leukopenia | Anemia | Oral administration | Etoposide | Breast cancer | Pharmacology | Patients | Cisplatin | Chemotherapy | Inhibitors | Solid tumors | Leukocytes (granulocytic) | Pharmacokinetics | Prostate cancer | Prostate | Cancer | Index Medicus
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 04/2000, Volume 6, Issue 4, pp. 1205 - 1218
Journal Article
Proteome Science, ISSN 1477-5956, 10/2008, Volume 6, Issue 1, pp. 27 - 27
Background: The development of mass spectrometric techniques and fractionation methods now allows the investigation of very complex protein mixtures ranging... 
ABSOLUTE QUANTITATION ITRAQ | HUMAN PLASMA | SHOTGUN PROTEOMICS | BIOCHEMICAL RESEARCH METHODS | 1ST-DIMENSION | LINE SH-SY5Y | IDENTIFICATION | PROTEINS | IMMOBILIZED PH GRADIENTS | MASS-SPECTROMETRY | ISOBARIC TAGS | Technology application | Methods | Proteomics
Journal Article
Cancer Research, ISSN 0008-5472, 07/2016, Volume 76, Issue 14 Supplement, pp. 439 - 439
Journal Article
Journal Article
Journal Article